Literature DB >> 23274789

Lactobacillus priming of the respiratory tract: Heterologous immunity and protection against lethal pneumovirus infection.

Katia E Garcia-Crespo1, Calvin C Chan, Stanislaw J Gabryszewski, Caroline M Percopo, Peter Rigaux, Kimberly D Dyer, Joseph B Domachowske, Helene F Rosenberg.   

Abstract

We showed previously that wild-type mice primed via intranasal inoculation with live or heat-inactivated Lactobacillus species were fully (100%) protected against the lethal sequelae of infection with the virulent pathogen, pneumonia virus of mice (PVM), a response that is associated with diminished expression of proinflammatory cytokines and diminished virus recovery. We show here that 40% of the mice primed with live Lactobacillus survived when PVM challenge was delayed for 5months. This robust and sustained resistance to PVM infection resulting from prior interaction with an otherwise unrelated microbe is a profound example of heterologous immunity. We undertook the present study in order to understand the nature and unique features of this response. We found that intranasal inoculation with L. reuteri elicited rapid, transient neutrophil recruitment in association with proinflammatory mediators (CXCL1, CCL3, CCL2, CXCL10, TNF-alpha and IL-17A) but not Th1 cytokines. IFNγ does not contribute to survival promoted by Lactobacillus-priming. Live L. reuteri detected in lung tissue underwent rapid clearance, and was undetectable at 24h after inoculation. In contrast, L. reuteri peptidoglycan (PGN) and L. reuteri genomic DNA (gDNA) were detected at 24 and 48h after inoculation, respectively. In contrast to live bacteria, intranasal inoculation with isolated L. reuteri gDNA elicited no neutrophil recruitment, had minimal impact on virus recovery and virus-associated production of CCL3, and provided no protection against the negative sequelae of virus infection. Isolated PGN elicited neutrophil recruitment and proinflammatory cytokines but did not promote sustained survival in response to subsequent PVM infection. Overall, further evaluation of the responses leading to Lactobacillus-mediated heterologous immunity may provide insight into novel antiviral preventive modalities. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274789      PMCID: PMC3608699          DOI: 10.1016/j.antiviral.2012.12.022

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  55 in total

Review 1.  Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methods.

Authors:  B E Steinberg; N M Goldenberg; W L Lee
Journal:  Antiviral Res       Date:  2011-11-02       Impact factor: 5.970

Review 2.  Regulation of epithelial immunity by IL-17 family cytokines.

Authors:  Rajita Pappu; Sascha Rutz; Wenjun Ouyang
Journal:  Trends Immunol       Date:  2012-04-02       Impact factor: 16.687

Review 3.  Nod2: a key regulator linking microbiota to intestinal mucosal immunity.

Authors:  Amlan Biswas; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Mol Med (Berl)       Date:  2011-08-23       Impact factor: 4.599

4.  Probiotic genomic DNA reduces the production of pro-inflammatory cytokine tumor necrosis factor-alpha.

Authors:  Chung Hee Kim; Han Geun Kim; Joo Yun Kim; Na Ra Kim; Bong Jun Jung; Ji Hye Jeong; Dae Kyun Chung
Journal:  FEMS Microbiol Lett       Date:  2012-01-06       Impact factor: 2.742

5.  Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice.

Authors:  Ha-Na Youn; Dong-Hun Lee; Yu-Na Lee; Jae-Keun Park; Seong-Su Yuk; Si-Yong Yang; Hyun-Jeong Lee; Seo-Hyung Woo; Hyoung-Moon Kim; Joong-Bok Lee; Seung-Yong Park; In-Soo Choi; Chang-Seon Song
Journal:  Antiviral Res       Date:  2011-11-19       Impact factor: 5.970

6.  NOD2 signaling contributes to host defense in the lungs against Escherichia coli infection.

Authors:  Balamayooran Theivanthiran; Sanjay Batra; Gayathriy Balamayooran; Shanshan Cai; Koichi Kobayashi; Richard A Flavell; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2012-04-30       Impact factor: 3.441

Review 7.  Type I interferon response to extracellular bacteria in the airway epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Trends Immunol       Date:  2011-10-11       Impact factor: 16.687

Review 8.  Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  Regulatory role of suppressive motifs from commensal DNA.

Authors:  N Bouladoux; J A Hall; J R Grainger; L M dos Santos; M G Kann; V Nagarajan; D Verthelyi; Y Belkaid
Journal:  Mucosal Immunol       Date:  2012-05-23       Impact factor: 7.313

10.  Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection.

Authors:  François Coulombe; Stéphanie Fiola; Shizuo Akira; Yvon Cormier; Jean Gosselin
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

View more
  28 in total

1.  Immortalized MH-S cells lack defining features of primary alveolar macrophages and do not support mouse pneumovirus replication.

Authors:  Todd A Brenner; Tyler A Rice; Erik D Anderson; Caroline M Percopo; Helene F Rosenberg
Journal:  Immunol Lett       Date:  2016-02-23       Impact factor: 3.685

2.  Administration of immunobiotic Lactobacillus plantarum delays but does not prevent lethal pneumovirus infection in Rag1-/- mice.

Authors:  Caroline M Percopo; Michelle Ma; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2017-06-15       Impact factor: 4.962

Review 3.  The influence of the microbiota on the immune response to transplantation.

Authors:  Caroline Bartman; Anita S Chong; Maria-Luisa Alegre
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

Review 4.  Role of the microbiota in immunity and inflammation.

Authors:  Yasmine Belkaid; Timothy W Hand
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

5.  Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection - a randomised controlled trial.

Authors:  R B Turner; J A Woodfolk; L Borish; J W Steinke; J T Patrie; L M Muehling; S Lahtinen; M J Lehtinen
Journal:  Benef Microbes       Date:  2017-03-27       Impact factor: 4.205

6.  Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.

Authors:  Caroline M Percopo; Tyler A Rice; Todd A Brenner; Kimberly D Dyer; Janice L Luo; Kishore Kanakabandi; Daniel E Sturdevant; Stephen F Porcella; Joseph B Domachowske; Jesse D Keicher; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2015-07-02       Impact factor: 5.970

7.  Silkworm larvae plasma (SLP) assay for detection of bacteria: False positives secondary to inflammation in vivo.

Authors:  Michelle Ma; Tyler A Rice; Caroline M Percopo; Helene F Rosenberg
Journal:  J Microbiol Methods       Date:  2016-11-10       Impact factor: 2.363

8.  Compartmentalized and systemic control of tissue immunity by commensals.

Authors:  Yasmine Belkaid; Shruti Naik
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

9.  Sustained inflammation and differential expression of interferons type I and III in PVM-infected interferon-gamma (IFNγ) gene-deleted mice.

Authors:  Stephanie F Glineur; Aaron B Bowen; Caroline M Percopo; Katia E Garcia-Crespo; Kimberly D Dyer; Sergei I Ochkur; Nancy A Lee; James J Lee; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virology       Date:  2014-08-28       Impact factor: 3.616

10.  B cells are not essential for Lactobacillus-mediated protection against lethal pneumovirus infection.

Authors:  Caroline M Percopo; Kimberly D Dyer; Katia E Garcia-Crespo; Stanislaw J Gabryszewski; Arthur L Shaffer; Joseph B Domachowske; Helene F Rosenberg
Journal:  J Immunol       Date:  2014-04-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.